Table 2 Expression of EGFR, β-catenin, CEA, c-Myc and Ki-67 antibodies and their association with other clinical, biological, histopathological and genetic features of sporadic colorectal cancer patients (n = 51).

From: Prognostic implications of EGFR protein expression in sporadic colorectal tumors: Correlation with copy number status, mRNA levels and miRNA regulation

Variable

EGFR

p

β-catenin

p

CEA

p

c-Myc

p

Ki-67

p

<35%

≥35%

−

+

−

+

<10%

≥10%

<50%

≥50%

Age (years)

<72

21 (78)

6 (22)

NS

15 (55)

12 (45)

NS

5 (19)

22 (81)

NS

6 (22)

21 (78)

NS

20 (74)

7 (26)

NS

≥72

15 (65)

8 (35)

 

14 (61)

9 (39)

 

6 (26)

17 (74)

 

3 (17)

18 (83)

 

15 (65)

8 (35)

Gender

Male

25 (68)

12 (32)

NS

23 (62)

14 (38)

NS

9 (24)

28 (76)

NS

7 (19)

29 (81)

NS

24 (65)

13(35)

NS

Female

11 (85)

2 (15)

 

6 (46)

7 (54)

 

2 (15)

11 (85)

 

2 (17)

10 (83)

 

11 (85)

2(15)

Site of primary tumor

Colon

28 (76)

9 (24)

NS

22 (59)

15 (41)

NS

11 (30)

26 (70)

0.030

5 (14)

31 (86)

NS

25 (68)

12 (32)

NS

Rectum

8 (62)

5 (38)

 

7 (46)

6 (54)

 

0 (0)

13 (100)

 

4 (33)

8 (67)

 

10 (77)

3 (23)

Histopathological grade

Well differentiated

24 (71)

10 (39)

 

20 (59)

14 (41)

 

7 (21)

27 (79)

 

7 (21)

26 (79)

 

21 (62)

13 (38)

NS

Moderately differentiated

11 (79)

3 (21)

NS

8 (57)

6 (43)

NS

4 (29)

10 (71)

NS

2 (14)

12 (86)

NS

12 (86)

2 (14)

Poorly differentiated

1 (50)

1 (50)

 

1 (50)

1 (50)

 

0 (0)

2 (100)

 

0 (0)

1 (100)

 

2 (100)

0 (0)

pT stage

T1-T2

8 (100)

0

NS

3 (38)

5 (62)

NS

3 (38)

5 (62)

0.007

0 (0)

8 (100)

NS

5 (62)

3 (38)

NS

T3-T4

28 (67)

14 (33)

 

16 (38)

26 (62)

 

8 (19)

34 (81)

 

9 (22)

31 (88)

 

30 (71)

12 (29)

Lymph node involvement

N0

30 (86)

5 (14)

0.001

21 (62)

13 (38)

NS

11 (44)

24 (56)

0.010

5 (15)

28 (85)

NS

24 (69)

11 (31)

NS

N1/N2

6 (40)

9 (60)

 

8 (50)

8 (50)

 

0 (0)

15 (100)

 

4 (27)

11 (73)

 

11 (73)

4 (27)

Liver metastases at diagnosis

No

29 (94)

2 (6)

<0.001

19 (63)

11 (37)

NS

11 (35)

20 (65)

0.003

3 (10)

26 (90)

NS

19 (61)

12 (39)

NS

Yes

7 (37)

12 (63)

 

10 (50)

10 (50)

 

0 (0)

19 (100)

 

6 (32)

13 (68)

 

6 (31)

13 (69)

pTNM stage at diagnosis

I

7 (100)

0

 

2 (29)

5 (71)

 

3 (43)

4 (57)

 

0 (0)

7 (100)

 

4 (57)

3 (43)

NS

II

19 (95)

1 (5)

<0.001

15 (79)

4 (21)

NS

6 (30)

14 (70)

0.007

2 (11)

16 (89)

0.030

12 (30)

18 (70)

III

3 (75)

1 (25)

 

2 (50)

2 (50)

 

2 (50)

2 (50)

 

1 (25)

3(75)

 

3 (75)

1 (25)

IV

7 (37)

12 (63)

 

10 (50)

10 (50)

 

0 (0)

19 (100)

 

6 (31)

13 (69)

 

16 (84)

3 (16)

Tumor size

<4 cm

8 (80)

2 (20)

NS

5 (50)

5 (50)

NS

0 (0)

10 (100)

NS

2 (20)

8 (80)

NS

9 (90)

1 (10)

NS

≥4 cm

28 (70)

12 (30)

 

24 (60)

16 (40)

 

11 (28)

29 (72)

 

7 (18)

31 (82)

 

26 (65)

14 (35)

Microsatellite instability

No

27 (66)

14 (34)

NS

20 (49)

21 (51)

0.007

4 (10)

37 (90)

<0.001

9 (23)

30 (77)

NS

32 (78)

9 (22)

0.030

Yes

8 (100)

0

 

8 (100)

0 (0)

 

8 (100)

0 (0)

 

0 (0)

8 (100)

 

3 (37)

5 (63)

KRAS mutation

No

35 (78)

10 (22)

0.001

26 (58)

19 (42)

NS

11 (24)

34 (76)

NS

7 (16)

36 (84)

NS

31 (69)

14 (31)

NS

Yes

0

4 (100)

 

3 (75)

1 (25)

 

0 (0)

4 (100)

 

2 (50)

2 (50)

 

3 (75)

1 (25)

NRAS mutation

No

33 (75)

11 (25)

NS

18 (53)

16 (47)

0.010

10 (23)

34 (77)

NS

8 (19)

34 (81)

NS

30 (68)

14 (32)

NS

Yes

2 (50)

2 (50)

 

0 (0)

4 (100)

 

1 (25)

3 (75)

 

0 (0)

4 (100)

 

3 (75)

1 (25)

BRAF mutation

No

31 (89)

4 (11)

NS

26 (58)

19 (42)

NS

8 (18)

37 (82)

0.008

8 (20)

31 (80)

NS

33 (73)

12 (28)

0.040

Yes

4 (100)

0

 

1 (25)

3 (75)

 

3 (75)

1 (25)

 

1 (25)

3 (75)

 

1 (25)

3 (75)

  1. Results expressed as number of cases (percentage); CEA: carcinoembryogenic antigen; NS: no statistically significant differences found between groups (p > 0.05).
Back to article page